ClinicalTrials.gg
CompletedNCT00877487Updated Jun 22, 2021Results posted

Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder

A Phase 4 interventional study of SPD489 (Lisdexamfetamine dimesylate) and Placebo in Attention-Deficit/Hyperactivity Disorder, sponsored by Shire. Completed at 55 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-06-22.

Sponsored by Shire (part of Takeda) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
19th of 51
123 · median 48
Started
2009
with 5 others
Phase 4
23 of 51
none open now
Registered
20th of 51
by date
Lead sponsor
18 of 51
Shire

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 19th largest by enrollment, is one of 6 that started in 2009, is one of 23 in phase 4, and was the 20th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the maintenance of efficacy, as measured by Adult ADHD Rating Scale with Prompts (Adult ADHD-RS with prompts) and Clinical Global Impression - Severity (CGI-S) scores, through a randomized withdrawal design when subjects with ADHD have been on stable treatment with commercial SPD489 for a minimum of 6 months and are maintained on their screening dose of commercial SPD489.

03

Conditions studied

  • Attention-Deficit/Hyperactivity Disorder

Keywords

  • ADHD
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject must be 18-55 years of age, inclusive at the time of consent.
  2. Female subjects must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test at Screening and a negative urine pregnancy test at baseline and agree to comply with any applicable requirements of the protocol.
  3. Subject has a documented diagnosis of ADHD or meets ™ with adult prompts criteria by history for a primary diagnosis of ADHD prior to treatment.
  4. Subject has a Baseline score of \<22 using the Adult ADHD-RS with prompts and CGI-S score ≤3.
  5. Subject has been on stable treatment with commercial SPD489 (30, 50, or 70mg) for a minimum of at least 6 months preceding the Screening Visit with acceptable tolerability.Prior treatment with commercial SPD489 in the 6 months preceding the Screening Visit must be documented by prescription records, prescribing physician notes, or pharmacy records. Those subjects whose primary care physician (PCP) is someone other than the Principal Investigator (PI) will be required to provide the above documentation to the site.
  6. Subject must have a minimum level of intellectual functioning, as determined by the Investigator.
  7. Subject is willing and able to comply with all the testing and requirements defined in this protocol.
  8. Subject is able to swallow a capsule.
  9. Subject must be able to provide written, personally signed and dated to participate in the study, in accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E627 and applicable regulations, before completing any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subject has a current comorbid psychiatric disorder that is either controlled with medications prohibited in this study or is uncontrolled and associated with significant symptoms. Prohibited disorders include those associated with diagnoses including but not limited to any severe comorbid Axis II disorder or severe Axis I disorder (such as Post Traumatic Stress Disorder [PTSD], psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder). Other symptomatic manifestations (such as agitated states)that contraindicate treatment with SPD489 or confound efficacy or safety assessments in the opinion of the examining physician are also prohibited. Comorbid psychiatric diagnoses will be established by the psychiatric evaluation that includes the Structured Clinical Interview for ™ disorders (SCID-I).
  2. Subject is currently considered a suicide risk, has previously made a suicide attempt or has a prior history of, or is currently demonstrating suicidal ideation.
  3. The subject has a (BMI) of \<18.5 or ≥40.
  4. Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition that might confound the results of safety assessments administered in the study or that might increase risk to the subject. Similarly, the subject will be excluded if he or she has any additional condition(s) that in the Investigator's opinion would prohibit the subject from completing the study or would not be in the best interest of the subject. This would include any significant illness or unstable medical condition that could lead to difficulty complying with the protocol. Mild, stable asthma is not exclusionary.
  5. Subject has a history of seizures (other than infantile febrile seizures), any tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder.
  6. Subject has known history of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or stroke or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
  7. Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
  8. Subject has any or clinically significant laboratory abnormality at Screening.
  9. Subject has current abnormal thyroid function, as defined as abnormal Screening thyroid stimulating hormone (TSH) and thyroxine (T4). Treatment with a stable dose of thyroid medication for at least 3 months is permitted.
  10. Subject has a history of moderate to severe hypertension or has a resting sitting systolic blood pressure >139mmHg or diastolic blood pressure >89mmHg. Subjects with well-controlled mild or moderate hypertension on a single antihypertensive agent are allowed.
  11. Subject is taking any medication that is excluded (Please refer to Table 2).
  12. Subject has a documented allergy, , or intolerance to amphetamines.
  13. Subject has a recent history (within the past 6 months) of suspected substance abuse or dependence disorder (excluding nicotine) in accordance with DSM-IV-TR™ criteria.
  14. Subject has a positive urine drug result at Screening (with the exception of subject's current stimulant therapy).
  15. Subject has taken an compound that has a central nervous system(CNS) effect or taken part in a clinical trial for ADHD 6 months prior to the Screening Visit.
  16. Subject has taken part in an investigational trial within the 30 days prior to the Screening Visit.
  17. Subject has glaucoma.
  18. Subject is taking other medications that have CNS effects or affect performance, such as chronic use of sedating antihistamines and decongestant sympathomimetics (7 days prior to Screening). Stable use of bronchodilator inhalers is not exclusionary.
  19. Subject is female and pregnant or lactating.
  20. Subjects who have previously been enrolled into this study and subsequently withdrawn.
  21. Subject is not well controlled on SPD489 with acceptable tolerability (Adult ADHD-RS with prompts score ≥22).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    SPD489

    Drug: SPD489 (Lisdexamfetamine dimesylate)

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 1 capsule (either 30, 50, or 70mg strength) per day for 6 weeks.

    Also known as: Vyvanse

  • DrugPlacebo

    1 capsule (identical to drug capsules) per day for 4 weeks during the double blind period.

06

What researchers measure

Primary outcomes

  1. Percent of Treatment Failures at up to 6 Weeks

    Treatment failure defined as \> or equal to 50% increase in the ADHD-RS with adult prompts total score and a \> or equal to 2 point increase in the CGI-S score.

    Time frame: Up to 6 weeks

Secondary outcomes

  1. Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) With Adult Prompts Total Score at up to 6 Weeks

    The ADHD-RS consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.

    Time frame: Up to 6 weeks

  2. Assessment of Clinical Global Impression-Severity of Illness (CGI-S) at up to 6 Weeks

    CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

    Time frame: Up to 6 weeks

07

Results

Posted Aug 2, 2011

Participant flow

Open-label Treatment Phase
Participant flow — Open-label Treatment Phase
MilestoneSPD489Placebo
Started1230
Completed1160
Not completed70
Withdrew: Adverse event10
Withdrew: Protocol violation30
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up10
Withdrew: Out of country for business10
Double-blind Randomized Withdrawal Phase
Participant flow — Double-blind Randomized Withdrawal Phase
MilestoneSPD489Placebo
Started5660
Completed5013
Not completed647
Withdrew: Relapse criteria met545
Withdrew: Adverse event01
Withdrew: Protocol violation01
Withdrew: Moved out of state10

Outcome measures

SecondaryChange From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) With Adult Prompts Total Score at up to 6 Weeks

The ADHD-RS consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.

Time frame:
Up to 6 weeks
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) With Adult Prompts Total Score at up to 6 Weeks
Units on a scaleSPD489Placebo
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS) With Adult Prompts Total Score at up to 6 Weeks1.6 ± 1.3916.8 ± 1.35
Statistical analysis
  • SPD489 vs Placebo · ANCOVA · p = <0.0001 · Mean difference (final values): -15.23 · 95% CI -19.1 to -11.4
SecondaryAssessment of Clinical Global Impression-Severity of Illness (CGI-S) at up to 6 Weeks

CGI-S assesses the severity of the subject's condition on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill)

Time frame:
Up to 6 weeks
Reported as:
Number · Percent of Participants
Assessment of Clinical Global Impression-Severity of Illness (CGI-S) at up to 6 Weeks
Percent of ParticipantsSPD489Placebo
Normal, not at all ill32.15.0
Borderline mentally ill35.711.7
Mildly ill17.911.7
Moderately ill7.133.3
Markedly ill7.135.0
Severely ill03.3
Among the most extremely ill00
Statistical analysis
  • SPD489 vs Placebo · Cochran-Mantel-Haenszel · p = <0.0001
PrimaryPercent of Treatment Failures at up to 6 Weeks

Treatment failure defined as \> or equal to 50% increase in the ADHD-RS with adult prompts total score and a \> or equal to 2 point increase in the CGI-S score.

Time frame:
Up to 6 weeks
Reported as:
Number · Percent of participants
Percent of Treatment Failures at up to 6 Weeks
Percent of participantsSPD489Placebo
Percent of Treatment Failures at up to 6 Weeks8.975.0
Statistical analysis
  • SPD489 vs Placebo · Chi-squared · p = <0.0001

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SPD489—0/56 (0%)16/56 (28.6%)
Placebo—1/60 (1.7%)6/60 (10%)
Most frequent serious events
Most frequent serious events
EventSPD489Placebo
Suicidal ideationPsychiatric disorders0/561/60
Most frequent other events
Most frequent other events
EventSPD489Placebo
HeadacheNervous system disorders8/563/60
Upper respiratory tract infectionInfections and infestations5/560/60
InsomniaPsychiatric disorders3/563/60

Baseline characteristics

Age, Continuous
Age, Continuous(years)SPD489
Mean35.4 ± 11.16
Age, Customized
Age, Customized(Participants)SPD489
Between 18 and 55 years122
Sex: Female, Male
Sex: Female, Male(Participants)SPD489
Female68
Male54
Region of Enrollment
Region of Enrollment(Participants)SPD489
United States122
08

Study locations

55 sites
  • Clinical Study Centers, LLC
    Little Rock, Arkansas 72205, United States
  • Valley Clinical Research, Inc.
    El Centro, California 92243, United States
  • Peninsula Research Associates, Inc
    Rolling Hills Estates, California 90274, United States
  • PCSD Feighner Research
    San Diego, California 92108, United States
  • Elite Clinical Trials, Inc.
    Wildomar, California 92595, United States
  • Colorado Clinica Trials, Inc.
    Highlands Ranch, Colorado 80130, United States
  • Florida Clinical Research Center
    Bradenton, Florida 34208, United States
  • Gulfcoast Clinical Research Center
    Fort Myers, Florida 33912, United States
  • Clinical Neuroscience Solutions Inc
    Jacksonville, Florida 32216, United States
  • Fidelity Clinical Research, Inc.
    Lauderhill, Florida 33319, United States
  • CNS Healthcare
    Orlando, Florida 32806, United States
  • Miami Research Associates
    South Miami, Florida 33143, United States
  • Janus Center for Psychiatric Research
    West Palm Beach, Florida 33407, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30308, United States
  • Northwest Behavioral Research Center
    Roswell, Georgia 30076, United States
  • Joliet Center for Clinical Research
    Joliet, Illinois 60435, United States
  • Capstone Clinical Research
    Libertyville, Illinois 60048, United States
  • CIENTIFICA, Inc
    Newton, Kansas 67114, United States
  • Psychiatric Associates
    Overland Park, Kansas 66211, United States
  • Vince and Associates Clinical Research
    Overland Park, Kansas 66212, United States
  • Clinical Trial Technology Inc.
    Prairie Village, Kansas 66206, United States
  • Pedia Research LLC
    Owensboro, Kentucky 42301, United States
  • Four Rivers Clinical Research
    Paducah, Kentucky 42003, United States
  • Rockville, Maryland 20852, United States
  • Rochester Center for Behavioral Medicine
    Rochester Hills, Michigan 48307, United States
  • The Behavioral Medicine Clinic of NW Michigan
    Traverse City, Michigan 49686, United States
  • Behavioral Medical Center-Troy
    Troy, Michigan 48083, United States
  • Midwest Research Group/ St. Charles Psychiatric Associates
    Saint Charles, Missouri 63301, United States
  • Premier Psychiatric Research Institute, LLC
    Lincoln, Nebraska 68510, United States
  • Center for Psychiatry and Behavioral Medicine Inc.
    Las Vegas, Nevada 89128, United States
  • Center for Emotional Fitness
    Cherry Hill, New Jersey 08002, United States
  • Global Medical Institutes, LLC. Princeton Medical Institute
    Princeton, New Jersey 08540, United States
  • Richmond Behavioral Associates
    Staten Island, New York 10312, United States
  • Richard H. Weisler, MD, PA & Associates
    Raleigh, North Carolina 27609, United States
  • Prarie St. Johns/ Odyssey Research
    Fargo, North Dakota 58104, United States
  • UHCMC/ Discovery and Wellness Center for Children
    Cleveland, Ohio 44106, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73703, United States
  • Calcagno Pediatrics
    Gresham, Oregon 97030, United States
  • Introspect of Buxmont, Ltd.
    Colmar, Pennsylvania 18915, United States
  • Youth and Family Research Program
    Pittsburgh, Pennsylvania 15213, United States
  • Carolina Clinical Trials, Inc.
    Charleston, South Carolina 29407, United States
  • CNS Healthcare
    Memphis, Tennessee 38119, United States
  • FutureSearch Trials
    Austin, Texas 78756, United States
  • FutureSearch Trials of Dallas, LP
    Dallas, Texas 75231, United States
  • Bayou City Reserch, Ltd.
    Houston, Texas 77007, United States
  • Westex Clinical Investigators
    Lubbock, Texas 79423, United States
  • Cerebral Research, LLC
    San Antonio, Texas 78247, United States
  • Aspen Clinical Research
    Orem, Utah 84058, United States
  • Vermont Clinical Study Center
    Burlington, Vermont 05401, United States
  • Neuropsychiatric Associates
    Woodstock, Vermont 05091, United States
  • Psychiatric Alliance of the Blue Ridge
    Charlottesville, Virginia 22903, United States
  • Dominion Clinical Research
    Midlothian, Virginia 23112, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98004, United States
  • Eastside Therapeutic Resource
    Kirkland, Washington 98033, United States
  • Dean Foundation
    Middleton, Wisconsin 53562, United States
09

References and documents

Publications

  • Brams M, Weisler R, Findling RL, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012 Jul;73(7):977-83. doi: 10.4088/JCP.11m07430. Epub 2012 Jun 12. PubMed 22780921 ↗
  • Weisler RH, Babcock T, Adeyi B, Brams M. Relationship of ADHD symptoms and global illness severity in adults treated with lisdexamfetamine dimesylate. Postgrad Med. 2014 Sep;126(5):31-41. doi: 10.3810/pgm.2014.09.2798. PubMed 25295648 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2009 to primary completion in Jul 2010, 14 months.

Results were first posted in Aug 2011, 1 year after primary completion.

Of 62 phase 4 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 70. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2009
First posted
Apr 7, 2009
StartActual
Apr 30, 2009
Primary completionActual
Jul 8, 2010
CompletionActual
Jul 8, 2010
Results first posted
Aug 2, 2011
Last update
Jun 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00877487
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Apr 7, 2009
Start date
Apr 30, 2009
Primary completion
Jul 8, 2010
Completion
Jul 8, 2010
Results posted
Aug 2, 2011
Last update
Jun 22, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion